Cost Effectiveness of Venous Leg Ulcer Healing Using Muscle Pump Activation

Int Wound J. 2026 Aug;23(8):e71014. doi: 10.1111/iwj.71014.ABSTRACTThe aim of this study was to evaluate the cost-effectiveness of treating patients with Venous Leg Ulcers (VLUs) with the Muscle Pump Activation device (MPA, geko) in Canada. This is a cost-effectiveness analysis of the treatment of p

M Michael C Stacey

Advances in Health-Related Quality of Life in Primary Ciliary Dyskinesia

Pediatr Pulmonol. 2026 Aug;61(8):e71785. doi: 10.1002/ppul.71785.ABSTRACTINTRODUCTION: Primary ciliary dyskinesia (PCD) is a rare, genetic disorder characterized by impaired mucociliary clearance and progressive sino-pulmonary disease. Individuals have chronic, progressive chest symptoms throughout

A Alexandra L Quittner

Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators

Small. 2026 Aug 12:e75181. doi: 10.1002/smll.75181. Online ahead of print.ABSTRACTNanozymes are engineered nanomaterials possessing intrinsic enzyme-mimetic catalytic activities that enable regulation of reactive oxygen species (ROS). Initially developed for superoxide dismutase-, catalase-, and per

S Sumi Choi

Gastrointestinal Symptom-Specific Anxiety Predicts Positive SCOFF Screens in Adults With Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorder and May Overestimate Eating Disorder Risk

Neurogastroenterol Motil. 2026 Aug;38(8):e70417. doi: 10.1111/nmo.70417.ABSTRACTBACKGROUND/AIMS: The Sick, Control, One, Fat, Food (SCOFF) is a questionnaire that screens for risk of eating disorders. Some symptoms and psychological factors associated with disorders of gut-brain interaction (DGBI) m

R Reem Altuwayjiri

The Role of Wearable Devices in the Management of Congenital Heart Disease

J Clin Med. 2026 Aug 6;15(15):6111. doi: 10.3390/jcm15156111.ABSTRACTPatients with congenital heart disease (CHD) represent a special healthcare challenge due to their high complexity, which accompanies them throughout all life stages. Consequently, this population faces increased morbidity and mort

I Inés Martínez-Saludes

Anti-Obesity Medications in Longevity and Aesthetic Medicine

J Clin Med. 2026 Aug 3;15(15):6026. doi: 10.3390/jcm15156026.ABSTRACTAnti-obesity medications (AOMs), led by the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and liraglutide and the dual GIP/GLP-1 receptor agonist tirzepatide, have produced substantial weight reduction and growi

J Julia Bijoch